| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Methyl 2-acetoxybenzoate targets inflammatory pathways as an aspirin prodrug. As an acetylsalicylic acid derivative, it is expected to be hydrolyzed to salicylic acid, which inhibits cyclooxygenase (COX) enzymes and reduces prostaglandin synthesis. The compound's anti-inflammatory activity is mediated through its conversion to the active salicylate. Its ester nature allows for prodrug properties that may affect its absorption and pharmacokinetics. The compound's use in proteomics research suggests applications in studying protein interactions and modifications.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that Methyl 2-acetoxybenzoate is a safe and simple anti-inflammatory aspirin prodrug. The compound's chemical properties have been characterized, including its appearance as colorless flaky crystals with a melting point of 51-52°C. It is soluble in ethanol, ether, and chloroform. These in vitro studies provide foundational data for understanding the compound's properties and its potential applications in anti-inflammatory research and proteomics studies.
|
| ln Vivo |
In vivo studies of Methyl 2-acetoxybenzoate are limited as the compound is primarily used as a research chemical. As an aspirin prodrug, it would be hydrolyzed in vivo to salicylic acid, which exerts anti-inflammatory effects. The compound's ester nature may affect its absorption and pharmacokinetic properties compared to aspirin. However, comprehensive in vivo pharmacological studies specifically targeting Methyl 2-acetoxybenzoate are not well documented in the available literature. The compound is intended for research use only and is not for human therapeutic use.
|
| Enzyme Assay |
In vitro enzyme assays for Methyl 2-acetoxybenzoate typically involve testing its hydrolysis to salicylic acid and its anti-inflammatory activity. Esterase activity is measured by monitoring the release of salicylic acid using chromatographic methods. Cyclooxygenase (COX) inhibition assays are performed to assess anti-inflammatory activity. The compound's purity and identity are assessed using analytical chemistry methods such as nuclear magnetic resonance spectroscopy, high-performance liquid chromatography, and mass spectrometry. All assays are performed with appropriate controls and standardized protocols.
|
| Cell Assay |
In vitro cell-based assays for Methyl 2-acetoxybenzoate involve culturing cells to evaluate its anti-inflammatory effects. Cells are treated with varying concentrations of the compound and stimulated with inflammatory stimuli. Pro-inflammatory cytokine production (e.g., PGE2, TNF-α, IL-6) is measured by ELISA. Cell viability is assessed using MTT or similar colorimetric assays to ensure that observed effects are not due to cytotoxicity. For proteomics research, the compound is used to study protein interactions and modifications. All experiments are performed in triplicate with appropriate controls.
|
| Animal Protocol |
In vivo animal experiments for Methyl 2-acetoxybenzoate would be conducted to evaluate its anti-inflammatory activity. Animal models of inflammation such as carrageenan-induced paw edema or adjuvant-induced arthritis would be used. Animals would be administered the compound and inflammatory markers measured. Parameters assessed would include paw swelling, body weight, and inflammatory cytokine levels. Control groups receiving vehicle alone or aspirin would be included for comparison. All procedures would comply with institutional animal care and use committee guidelines. Comprehensive in vivo studies are not well documented in the available literature.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Methyl 2-acetoxybenzoate reflect its nature as an aspirin prodrug. It has a molecular weight of 194.19 and the molecular formula C10H10O4. The compound has a melting point of 51-52°C and a boiling point of 134-136°C (1.2 kPa). It is soluble in ethanol, ether, and chloroform, and slightly soluble in water. As an ester prodrug, it would be hydrolyzed by esterases to salicylic acid. Complete pharmacokinetic profiling including half-life, clearance, volume of distribution, and bioavailability would require further systematic studies.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Methyl 2-acetoxybenzoate has been evaluated in the context of its use as a research chemical. As an aspirin prodrug, it is expected to have a safety profile similar to aspirin, which is generally safe at therapeutic doses but can cause gastrointestinal irritation and bleeding at high doses. Proper handling procedures including use of personal protective equipment are recommended when working with pure compound. The compound is not approved for human therapeutic use and is intended for research purposes only. Long-term toxicity studies would be needed to fully establish its safety profile.
|
| References | |
| Additional Infomation |
It has fewer gastrointestinal side effects compared to aspirin; it is numbered 5886 in Merck Index 9.
Methyl 2-acetoxybenzoate (CAS# 580-02-9) is also known as Methyl acetylsalicylate, Acetylsalicylic Acid Methyl Ester, and Methyl Aspirin. It has the molecular formula C10H10O4 and a molecular weight of 194.19. The compound is a safe and simple anti-inflammatory aspirin prodrug. It appears as colorless flaky crystals with a melting point of 51-52°C and a boiling point of 134-136°C (1.2 kPa). It is soluble in ethanol, ether, and chloroform, and slightly soluble in water. The compound is an ester used in proteomics research. It is intended for research use only. |
| Molecular Formula |
C10H10O4
|
|---|---|
| Molecular Weight |
194.18
|
| Exact Mass |
194.058
|
| CAS # |
580-02-9
|
| PubChem CID |
68484
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.177g/cm3
|
| Boiling Point |
254.9ºC at 760mmHg
|
| Melting Point |
50°C
|
| Flash Point |
121.4ºC
|
| Index of Refraction |
1.51
|
| LogP |
1.398
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
14
|
| Complexity |
224
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(=O)OC1=CC=CC=C1C(=O)OC
|
| InChi Key |
ONWPLBKWMAUFGZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H10O4/c1-7(11)14-9-6-4-3-5-8(9)10(12)13-2/h3-6H,1-2H3
|
| Chemical Name |
methyl 2-acetyloxybenzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (514.99 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (12.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (12.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1499 mL | 25.7493 mL | 51.4986 mL | |
| 5 mM | 1.0300 mL | 5.1499 mL | 10.2997 mL | |
| 10 mM | 0.5150 mL | 2.5749 mL | 5.1499 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
